Israel-Medical-Healthcare

[genisi]

Kamada is going to start a phase I/II safety and preliminary efficacy clinical trial of its IV Alpha-1 Antitrypsin (AAT) in type 1 diabetes. A couple of more recent basic research works in the area:

http://www.ncbi.nlm.nih.gov/pubmed/21099312

http://www.ncbi.nlm.nih.gov/pubmed/20692406

Baxter's Aralast is being tested by the NIAID for that indication: (looks like the trial is still in its first part (safety))

http://clinicaltrials.gov/ct2/show/NCT01183468

There is one commercial company trying to pursue the area:

http://www.omnibiopharma.com/development